The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retinal…
The most highly anticipated analgesic drugs in late-phase development belong to the anti-nerve growth factor (NGF) class: Pfizer / Eli Lilly’s tanezumab and Regeneron / Teva / Mitsubishi Tanabe…
The multiple sclerosis (MS) therapy market comprises more than a dozen disease-modifying therapies (DMTs) spanning a range of mechanisms of action, clinical profiles, formulations, and value…
The accelerated approvals of Kymriah (Novartis) for the treatment of children oryoung adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite Pharma, a Gilead…
MARKET OUTLOOKThe accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite…
MARKET OUTLOOKResearch on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. Significant…
MARKET OUTLOOKThe accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite…